Adverum Biotechnologies(ADVM) - 2025 Q1 - Quarterly Report

Financial Performance - As of March 31, 2025, the company had an accumulated deficit of $1.1 billion and has not generated positive cash flow or net income since inception [76]. - The operating loss for the three months ended March 31, 2025, was$48.2 million, an increase of $19.0 million from the operating loss of$29.2 million in the same period of 2024 [89]. - Net loss for the three months ended March 31, 2025, was $47.0 million, compared to a net loss of$27.1 million for the same period in 2024, reflecting an increase of $19.9 million [89]. - The company expects to continue incurring net losses and operating cash outflows for at least the next several years as it develops its product candidates [97]. - General and administrative expenses increased by$5.7 million to $19.5 million for the three months ended March 31, 2025, from$13.8 million in the same period of 2024 [92]. - Other income, net decreased by $0.9 million to$1.2 million for the three months ended March 31, 2025, from $2.1 million for the same period in 2024 [93]. Cash Flow and Funding - Cash and cash equivalents decreased to$83.1 million as of March 31, 2025, down from $125.7 million as of December 31, 2024 [94]. - Net cash used in operating activities was$42.8 million for the three months ended March 31, 2025, compared to $23.2 million for the same period in 2024 [105]. - The company plans to raise substantial additional funding to finance operations through various means, including public or private equity or debt financings [98]. - For the three months ended March 31, 2024, the net cash used in operating activities was$23.2 million, primarily due to a net loss of $27.1 million from ongoing research and development activities [107]. - The net cash provided by financing activities for the three months ended March 31, 2024 was primarily$119.7 million from the issuance of common stock and Pre-Funded Warrants in Private Placements [109]. - Additionally, $0.1 million was generated from the exercise of stock options during the same period [109]. Research and Development - The company announced top-line 52-week results from the LUNA Phase 2 clinical trial, showing a reduction in annualized anti-VEGF injection rates of 88$13.3 million to $28.7 million for the three months ended March 31, 2025, compared to$15.4 million for the same period in 2024 [90]. Operational Status - The company has not generated any revenue from product sales to date, relying on research and collaboration arrangements for revenue [80]. - The company currently has no operational clinical or commercial manufacturing facilities, relying on third-party contractors for clinical manufacturing [78].